Physician profile
Ray Lin
NPI 1649693540
$10,254.49
in general payments reported to CMS, 2019-2025
22 companies · $2,858 in 2025
The $2,858 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $795 · 2022: $888 · 2023: $2,343 · 2024: $3,370 · 2025: $2,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,377 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,377.19 |
| Education | $194.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,010.13 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,501.10 | 2023-2024 | Vtama |
| Abbvie INC. | $1,071.98 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $995.84 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $862.22 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $654.94 | 2021-2025 | |
| Leo Pharma INC. | $619.33 | 2022-2025 | Adbry |
| Incyte Corporation | $605.14 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $295.52 | 2022-2025 | Tremfya |
| Pfizer INC. | $287.49 | 2021-2024 | |
| Depuy Synthes Sales INC. | $252.81 | 2024 | Na |
| Arcutis Biotherapeutics, INC. | $244.82 | 2023-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $175.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $170.33 | 2023-2025 | Sotyktu |
| Ucb, INC. | $149.05 | 2022-2025 | Bimzelx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $96.93 | 2023-2024 | Winlevi |
| Sanofi-Aventis U.S. LLC | $72.31 | 2021 | |
| Galderma Laboratories, L.P. | $61.36 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $50.60 | 2022-2024 | Olumiant, Taltz |
| Organon LLC | $42.99 | 2025 | Vtama |
| Journey Medical Corporation | $21.29 | 2023 | |
| Boston Scientific Corporation | $13.31 | 2023 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.